Skip to main content

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

ACCLARENT AERA® Eustachian Tube TreatmentSimulation of a minimally invasive ear procedure using the ACCLARENT AERA® Eustachian Tube Treatment.PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California. At this year’s meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ENT and Laparoscopy Instruments, Bien-Air® Drill and Shaver Systems and RELIEVA SPINPLUS® Balloon Sinuplasty System. Additionally,...

Continue reading

Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells

New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, has identified pancreatic proenzyme formulation, PRP, as a potential strategy for addressing chemotherapy resistance in pancreatic cancer. Chemotherapy-resistant tumor cells can acquire adaptive cellular states that allow them to survive treatment and maintain aggressive characteristics. The study investigated...

Continue reading

Private Bancorp of America, Inc. Announces Strong Net Income for Third Quarter 2026

Third Quarter 2026 HighlightsNet income for the third quarter of 2026 was $11.4 million, compared to $13.1 million in the prior quarter and $9.7 million in the third quarter of 2025. Net income for the third quarter of 2026 represents a return on average assets of 1.65% and a return on average tangible common equity(1) of 15.62%. Diluted earnings per share for the third quarter of 2026 was $1.97, compared to $2.27 in the prior quarter and $1.65 in the third quarter of 2025. Core deposits were $2.36 billion as of September 30, 2026, an increase of $31.8 million, or 1.4%, from June 30, 2026, and an increase of $171.5 million, or 7.8%, from September 30, 2025. Total deposits were $2.41 billion. There was no change to the balance in brokered deposits. Total cost of deposits was 1.66% for the third quarter of 2026, compared to 1.63% in the...

Continue reading

Aduro Clean Technologies Reports First Quarter Fiscal Year 2027 Results and Provides Business Update

LONDON, Ontario, Oct. 16, 2026 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (TSX: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, has filed its interim condensed consolidated financial results for the three months ended August 31, 2026, and is pleased to provide the following highlights. Unless otherwise indicated, all financial information in this press release is reported in Canadian dollars. “During the first quarter of fiscal 2027, Aduro continued to advance and build on its progress at both the NGP Pilot Plant and across other areas, including engineering, feedstock, and commercial activities necessary for industrial deployment,”...

Continue reading

Royalty Pharma declares fourth quarter 2026 dividend

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on December 10, 2026, to shareholders of record at the close of business on November 13, 2026. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s...

Continue reading

Biomerica Reports First Quarter Fiscal 2027 Financial Results

InFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods® IBS update: 100% of all initial valid Medicare claims processed as of October 15, 2026 have been paid at the full CMS payment rate of $300Engaged B. Riley Securities, Inc. to support the Board’s ongoing evaluation of potential strategic opportunities, including partnerships and business combinationsTotal operating expenses decreased approximately 14% year over yearOver-the-counter sales increased approximately 81% compared to the first quarter of fiscal 2026Cash and cash equivalents more than doubled to approximately $2.7 million at August 31, 2026, from approximately $1.3 million at May 31, 2026IRVINE, Calif., Oct. 16, 2026 (GLOBE...

Continue reading

Geely Auto Group to Offer Customers Greater Choice Through Google Built-In

HANGZHOU, China, Oct. 16, 2026 (GLOBE NEWSWIRE) — Geely Holding Group (ZGH) today announced a global strategic partnership with Google to bring built-in Google Automotive Services to digital cockpits in all eligible ZGH portfolio brand vehicles in overseas markets where Google services are available. The first vehicle application is planned for the second half of 2027 in global markets outside of China and the United States, subject to applicable product, regulatory and market-readiness requirements.At roll-out, eligible ZGH overseas vehicles will come with built-in Google services including Google Gemini, Play, Maps and more. This fully integrated system delivers a comprehensive set of capabilities featuring a multimodal intelligent voice large model, global smart navigation, seamless cross-device connectivity, and an extensive...

Continue reading

Quantum X Labs’ Cybersecurity Technology Achieves Significant Breakthrough with IBM Quantum Hardware

LayerQake reduced maximum cumulative error by 15- to 21-fold and lowered measurement bias from approximately 11%–15% to below 6% across three IBM quantum processors, demonstrating the potential of Quantum X Labs’ quantum calibration technology TEL AVIV, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (NASDAQ: QXL) (“Quantum X Labs” or the “Company”), a quantum technology company developing solutions across quantum computing, quantum software, quantum cybersecurity and quantum sensing, today announced a technological milestone achieved by its quantum cybersecurity operation, QuantumQ Security, through the experimental validation of its LayerQake technology on three operational IBM quantum processors. The Company completed a pre-registered, reproducible experimental test of LayerQake’s quantum...

Continue reading

Future Mineral Announces Amendment to Purchase Agreement Respecting Acquisition of Nickel–Zinc–Lead Project in Poland

TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) — Future Mineral Resources Inc. (“Future Mineral” or the “Company”) (TSX: FMR) is pleased to announce that it has entered into an amendment (the “Amendment”) to the share purchase agreement dated February 2, 2026 (the “Agreement”) to acquire the remaining 52% ownership interest in its flagship nickel–zinc–lead project in Poland (the “Project”). The Agreement was initially entered into with Forbes EV Metals Inc. (the “Target”) and its shareholders, many of whom are current or former directors and officers of the Company (collectively, the “Vendors”), pursuant to which Future Mineral intends to indirectly acquire (the “Acquisition”) the remaining 52% interest in the Project through the purchase of 100% of the issued and outstanding shares of the Target, which owns 52% of Ferrite Resources Polska...

Continue reading

Zenta Group Subsidiary ZentoAI Signs Binding MOU For Strategic Acquisition

Proposed acquisition of controlling stake in a mainland China based digital technology service provider to expand AI and data solutions MACAU, Oct. 16, 2026 (GLOBE NEWSWIRE) — Zenta Group Company Limited (“Zenta Group” or the “Company”) (Nasdaq: ZTG), a Macau-based professional services provider which has recently re-aligned its business focus toward AI and data solutions, today announces that its subsidiary, ZentoAI Intelligent Technology Company Limited (“ZentoAI”), has executed a binding Memorandum of Understanding (the “MOU”) to acquire a controlling stake in a privately held digital technology service provider in mainland China (the “Target”). The Target is a profitable digital technology service provider anchored in “AI + Big Data”. Its technical framework incorporates advanced capabilities in privacy‑computing, large‑language‑model...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.